Introduction {#sec1}
============

Artemisinin (**1**) is a sesquiterpene from *Artemisia annua* L. (sweet wormwood)^[@ref1]^ characterized by a reactive 1,2,4-trioxane ring (endoperoxide bridge) and a lactone moiety as pharmacophores ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref2]^ This compound is applied in the treatment of different types of malaria.^[@ref3]^ Semisynthetic derivatives of artemisinin, dihydroartemisinin **2**, artesunate **3**, and artemether **4**, have been developed with the aim of increasing the pharmacological activity and the pharmacokinetic profile of the parent drug ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref4]^ In addition, artemisinin and artemisinin derivatives showed remarkable activity against cancer cell lines,^[@ref5]^ including leukemia, melanoma, breast, ovarian, prostate, colon, and renal cancers, without inducing cytotoxicity in normal cells.^[@ref6]^ This selectivity is due to the iron-mediated cleavage of the endoperoxide bridge in tumor cells containing a higher concentration of this metal with respect to their normal cell counterpart.^[@ref7]^ Moreover, tumor cells usually show a diminished expression of antioxidant enzymes able to scavenge radical species.^[@ref8]^ Iron catalyzes the ring opening of the endoperoxide bridge of artemisinin, with subsequent generation of free-radical reactive oxygen and carbon-centered species,^[@ref9]^ followed by oxidative DNA damage. The mechanism is also responsible for the antimalarial effect of artemisinin, in which case the radical cascade is triggered by iron atoms delivered during the metabolic breakdown of hemoglobin in the vacuole of the parasite.^[@ref10]^

![Artemisinin and semisynthetic derivatives of artemisinin and phytochemicals.](ao9b02600_0002){#fig1}

Recently, the synthesis of hybrid and dimer derivatives of bioactive natural substances turned out to be a useful strategy to increase both biological activity and pharmacokinetic profiles, avoiding drug-resistance phenomena with respect to the individual starting compounds.^[@ref11]^ Dimers and hybrids of artemisinin and artemisinin derivatives in association with bioactive phytochemicals, such as thymoquinone, showed increased antileukemia and antimalarial activity.^[@ref12]^ Different dimers and hybrids of artemisinin derivatives containing natural phenol and catechol residues, such as 2-(3-hydroxyphenyl)ethanol and 3-hydroxytyrosol, have also been patented.^[@ref13]^

We report here the synthesis of a novel library of artemisinin-based hybrid and dimer derivatives obtained by chemical coupling of dihydroartemisinin **2** and artesunate **3** with chemopreventive phytochemicals, including curcumin **5**, eugenol **6**, perillyl alcohol **7**, tyrosol **8**, α-tocopherol **9**, and δ-tocopherol **10**, respectively ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref14]^ The products were evaluated on melanoma, the main cause of skin-cancer-related death and one of the most aggressive and lethal pathology in human.^[@ref15]^ In this context, phytochemicals **5--10** showed antimelanoma activity as isolated compounds or components of natural extracts.^[@ref16]−[@ref19]^

Results and Discussion {#sec2}
======================

Synthesis of Artemisinin-Based Hybrid and Dimer Derivatives {#sec2.1}
-----------------------------------------------------------

The hybrid derivatives of artemisinin, **11i**--**vi**, were synthesized by a procedure involving the reaction between artesunate **3** (1.0 mmol) and the appropriate phytochemical, **5**--**10** (1.1 mmol), in the presence of *N*,*N*′-dicyclohexylcarbodiimide (DCC) (1.2 mmol) and 4-dimethylaminopyridine (DMAP) (catalytic amount) as coupling agents ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). Compounds **11i**--**vi** were obtained, as the only recovered products, besides the unreacted substrate, from acceptable to high yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).

![Synthesis of Hybrid Derivatives **11i**--**iv**](ao9b02600_0016){#sch1}

###### Yield of Hybrid Derivatives **11i**--**iv** Obtained by the DCC/DMAP Coupling Reaction between Artesunate **3** and Phytochemicals **5--10**[a](#t1fn1){ref-type="table-fn"}^,^[b](#t1fn2){ref-type="table-fn"}

![](ao9b02600_0004){#fx11}

The reactions were performed by treating artesunate **3** (1.0 mmol) with DCC (1.2 mmol), DMAP (catalytic amount), and the appropriate phytochemical, **5**--**10** (1.1 mmol), at 25 °C for 18h.

Experiments were conducted in triplicate.

In addition, dimeric derivatives of artemisinin **11vii** and **11viii** were synthesized using phytochemicals bearing two reactive functional groups, such as curcumin **5** (two OH phenol moieties) and tyrosol **8** (OH phenol and primary alcohol moieties). In these latter cases, an excess of artesunate **3** (2.2 mmol) was required to optimize the yield of the desired product ([Chart [1](#cht1){ref-type="chart"}](#cht1){ref-type="chart"}). Note that compound **11viii** was characterized by a C-2 internal symmetry property.

![Structures of Dimeric Derivatives **11vii** and **11viii**](ao9b02600_0001){#cht1}

Finally, 4-hydroxyphenethyl bromide **12** was used as an electrophilic alkylating agent to obtain hybrid derivatives **11ix** and **11x** from artesunate **3** and dihydroartemisinin **2**, respectively ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). The reactions were performed under general basic catalysis conditions (K~2~CO~3~) in dimethylformamide (DMF, 10 mL) at 90 °C.

![Synthesis of Hybrid Derivatives **11ix** (46%) and **11x** (53%) from Artesunate **3** and Dihydroartemisinin **2**, respectively](ao9b02600_0017){#sch2}

In terms of structure relationships, compounds **11iv** and **11ix** were characterized by a different regioselectivity in the linkage of the tyrosol moiety to the artesunate scaffold, that is phenolic (**11iv**) versus primary alcohol (**11ix**) coupling site, respectively. The tyrosol moiety was linked to artesunate and dihydroartemisinin only by the primary alcoholic function in compounds **11ix** and **11x**.

Biological Activity {#sec2.2}
-------------------

Artemisinin derivatives can inhibit metastasis^[@ref20]^ and angiogenesis processes,^[@ref21]^ influencing some cancer-related signaling pathways.^[@ref22]^ We evaluated the anticancer activity of artemisinin **1**, dihydroartemisinin **2**, artesunate **3**, and artemisinin derivatives **11i**--**x** by cell survival \[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide\] (MTT) assay on a drug-resistant cervical cancer cell line (HeLa) and three complementary metastatic melanoma cancer cell lines, SK-MEL3, SK-MEL24, and RPMI-7951, respectively. The genetic characteristics of the SK-MEL3, SK-MEL24, and RPMI-7951 cell lines are summarized in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}. A normal human primary fibroblast cell line (C3PV) was used as a reference.

###### Genetic Properties of Melanoma Cancer Cell Lines Used in the Biological Evaluations

  name        mutant gene[a](#t2fn1){ref-type="table-fn"}   zygosity[b](#t2fn2){ref-type="table-fn"}   gene Seq.[c](#t2fn3){ref-type="table-fn"}   protein seq[d](#t2fn4){ref-type="table-fn"}
  ----------- --------------------------------------------- ------------------------------------------ ------------------------------------------- ---------------------------------------------
  SK-MEL3     BRAF                                          Heterozygous                               c.1799T\>A                                  p.V600E
  TP53        Homozygous                                    c.799 C\>T                                 p.R267W                                     
  RPMI-7951   BRAF                                          Heterozygous                               c.1799T\>A                                  p.V600E
  CDKN2A      Homozygous                                    c.47T\>G                                   p.L16R                                      
  PTEN        Homozygous                                    c.1_79del79                                                                            
  TP53        Homozygous                                    c.497C\>A                                  p.S166\*                                    
  SK-MEL24    BRAF                                          Heterozygous                               c.1799T\>A                                  p.V600E
  CDKN2A      Homozygous                                    c.1_471del471                                                                          
  PTEN        Homozygous                                    c.80_164del85                                                                          

These cell lines are characterized by mutations in different genes and gene regions that are representative of the metastatic melanoma.

Mutation state.

Mutation gene sequencing.

Mutation protein sequencing.

All three melanoma cell lines show the mutation of the B-RAF gene, which is involved in the regulation of the RAS/MAPK pathway, controlling cell proliferation, differentiation, migration, and apoptosis. The B-RAF gene mutation is highly frequent in both primary and metastatic melanoma cells, accounting for 50.9 and 66.3% of the total observed mutations, respectively.^[@ref23]^ Two cell lines, SK-MEL-3 and RPMI-7951, are mutated on the TP53 gene, which controls the synthesis of the p53 protein, involved in cell division and prevention of cancer formation.^[@ref24]^ Finally, the RPMI-7951 and SK-MEL24 cell lines were characterized by the cyclin-dependent kinase inhibitor 2A (CDKN2A)^[@ref25]^ and phosphatase and tensin homolog (PTEN)^[@ref26]^ gene mutations, controlling the production of tumor suppressor proteins.

Phytochemicals **5**--**10**, and the well-known anticancer drug, paclitaxel (Taxol), were used as references. [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"} reports the IC~50~ values (half-maximal inhibitory concentration) of the tested compounds. The stability of compound **11iv** in the cell culture medium has been evaluated by thin-layer chromatographic (TLC) and high-performance liquid chromatography (HPLC) analyses as a selected example. No traces of tyrosol were observed during 48 h, confirming the stability of the ester bond under the reported experimental conditions (see the Supporting Information [SI \#1--2 and Figures S1--S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02600/suppl_file/ao9b02600_si_001.pdf)).

###### Anticancer Activity of Artemisinin **1**, Dihydroartemisinin **2**, Artesunate **3**, Hybrid Derivatives **11i-iv** and **11ix-x**, and Dimeric Derivatives **11vii** and **11viii**[a](#t3fn1){ref-type="table-fn"}

                    IC~50~ ± SD[b](#t3fn2){ref-type="table-fn"}                                                   
  ---- ------------ --------------------------------------------- ---------------- -------------- --------------- --------------
  1    **1**        \>300 ± 14.85                                 1.37 ± 0.59      3.43 ± 0.86    8.66 ± 4.56     3.62 ± 0.99
  2    **2**        0.68 ± 0.19                                   1.32 ± 0.26      10.36 ± 0.61   3.23 ± 1.60     0.91 ± 0.45
  3    **3**        1.68 ± 0.44                                   1.76 ± 0.38      \>300 ± 5.07   0.82 ± 0.37     1.08 ± 0.56
  4    **11i**      2.36 ± 0.24                                   1.15 ± 1.09      3.23 ± 0.37    5.88 ± 2.25     10.43 ± 1.60
  5    **11ii**     6.79 ± 0.15                                   1.44 ± 1.09      4.65 ± 1.80    5.44 ± 2.4      1.21 ± 0.63
  6    **11iii**    \>300 ± 35.35                                 1.76 ± 0.47      5.24 ± 2.29    0.06 ± 0.1      2.35 ± 1.52
  7    **11iv**     \>300 ± 10.71                                 \>300 ± 7.071    2.33 ± 1.18    2.32 ± 1.19     8.34 ± 3.06
  8    **11v**      0.85 ± 0.32                                   4.39 ± 0.77      2.61 ± 0.49    \>300 ± 21.21   3.06 ± 0.17
  9    **11vi**     10.18 ± 1.57                                  3.34 ± 0.66      1.23 ± 0.83    3.69 ± 0.91     1.90 ± 0.35
  10   **11vii**    6.10 ± 3.74                                   2.16 ± 0.54      32.78 ± 5.81   0.24 ± 0.12     0.49 ± 0.05
  11   **11viii**   \>300 ± 14.84                                 2.41 ± 0.56      3.43 ± 0.16    2.54 ± 0.47     1.37 ± 0.13
  12   **11ix**     132.20 ± 12.58                                2.66 ± 0.82      1.28 ± 0.15    1.5 ± 0.85      0.09 ± 0.03
  13   **11x**      1.76 ± 0.31                                   2.73 ± 0.37      10.58 ± 1.14   3.01 ± 0.57     0.33 ± 0.08
  14   **5**        \>300 ± 31.82                                 2.12 ± 0.94      1.69 ± 1.24    3.00 ± 1.35     3.95 ± 0.09
  15   **6**        6.88 ± 0.085                                  4.68 ± 1.64      1.16 ± 0.32    2.61 ± 0.34     0.84 ± 0.34
  16   **7**        3.80 ± 0.28                                   1.63 ± 0.40      1.37 ± 0.59    2.69 ± 1.3      1.71 ± 0.52
  17   **8**        22.71 ± 1.83                                  1.41 ± 0.79      2.53 ± 1.41    1.69 ± 0.15     10.83 ± 1.40
  18   **9**        74.09 ± 5.09                                  3.03 ± 1.5       1.22 ± 0.64    2.35 ± 1.05     4.11 ± 2.1
  19   **10**       15.82 ± 0.97                                  4.01 ± 0.91      2.93 ± 0.15    5.57 ± 2.01     5.69 ± 1.91
  20   paclitaxel   78.88 ± 0.79                                  0.006 ± 0.0014   4.73 ± 0.83    1.04 ± 0.31     0.013 ± 0.19

All experiments were conducted in triplicate.

IC~50~ ± SD (half-maximal inhibitory concentration ± standard deviation) values for all compounds are expressed in micromolar units.

In the case of the HeLa cell line, artemisinin derivatives were less active than paclitaxel, with an antiproliferative effect comparable to that of artemisinin. The dimer, **11vii**, containing the tyrosol scaffold, showed a remarkable anticancer activity against both SK-MEL24 and RPMI-7951 melanoma cell lines, with IC~50~ values (0.24 and 0.49 μM, respectively) lower than, or comparable to, those of artemisinin and paclitaxel, respectively. Unfortunately, **11vii** was also characterized by a significant activity against the C3PV cell line. The dimer, **11viii**, containing the curcumin scaffold, was active against all melanoma cell lines studied, without any appreciable effect on the C3PV cell.

Note that perillyl alcohol **7** and tyrosol **8** showed higher activity and lower toxicity when incorporated into the artemisinin scaffold, as in the case of hybrids **11iii** ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entry 6 versus entry 16) and **11ix** ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entry 12 versus entry 17) against the SK-MEL24 and RPMI-7951 cell lines, respectively.

Compounds **11iv** and **11ix** showed antiproliferative activity against all studied melanoma cell lines, with acceptable tolerability toward the C3PV cell line. They were characterized by a toxicity higher than that of tyrosol **8**, highlighting a different effect of the artemisinin scaffold on the toxicity of the hybrid, depending on the nature of the associated phytochemical.

Artemisinin **1** and the novel artemisinin derivatives, **11iii**--**iv**, **11viii**, and **11ix**, were found to be cancer-selective, being not cytotoxic on normal cell line C3PV. Moreover, compound **11iv** possessed a melanoma-specific cancer selectivity (inactive against HeLa).

As a general trend, curcumin **5** was the most effective phytochemical in the dimer-type derivatives, whereas perillyl alcohol **7** and tyrosol **8** were the most effective in the hybrid-type compounds. Moreover, artesunate appeared to be the most active artemisinin derivative. To obtain information about the mechanism of action of compounds **11iii**--**iv**, **11viii**, and **11ix**, we repeated the cellular assays on the cancer lines in the presence of the iron chelating agent, deferoxamine (DFO),^[@ref27],[@ref28]^ able to inhibit the redox activation of the endoperoxide ring.

As reported in [Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}, the presence of DFO significantly lowered the efficacy of artemisinin **1**, confirming the beneficial role of iron in triggering the radical cascade mechanism responsible for the anticancer activity. A similar pathway was observed for compounds **11iv** and **11ix** containing the tyrosol scaffold. Instead, the anticancer activity of perillyl alcohol and curcumin in **11iii** and **11viii** was found to be independent from the presence of iron, suggesting the possibility of an alternative mechanism. Regarding the SK-MEL24 line, the activity of the four synthetic compounds seems to be not influenced by the iron chelation mediated by DFO.

###### IC~50~ Values of Compounds **11iii**, **11iv**, **11viii**, and **11ix** on the RPMI-7951, SK-MEL3, and SK-MEL24 Cancer Cell Lines in the Presence or Absence of DFO[a](#t4fn1){ref-type="table-fn"}^,^[b](#t4fn2){ref-type="table-fn"}

               IC50 ± SD[c](#t4fn3){ref-type="table-fn"}                                                           
  ------------ ------------------------------------------- ------------- ------------- ------------- ------------- -------------
  **1**        3.62 ± 1.6                                  28.97 ± 2.8   3.43 ± 0.8    \>300 ± 3.8   8.66 ± 0.9    27.8 ± 3.4
  **3**        1.08 ± 0.6                                  1.09 ± 0.9    \>300 ± 5.6   \>300 ± 4.5   0.82 ± 0.05   0.90 ± 0.02
  **11iii**    2.35 ± 0.9                                  2.95 ± 0.7    5.24 ± 0.2    5.6 ± 0.6     0.06 ± 0.01   0.16 ± 0.04
  **11iv**     8.34 ± 2.7                                  81.7 ± 5.7    2.33 ± 0.09   24.5 ± 1.3    2.32 ± 0.9    2.5 ± 0.6
  **11viii**   1.37 ± 0.9                                  1.18 ± 0.7    2.41 ± 0.8    3.8 ± 0.8     2.54 ± 0.5    3.3 ± 0.8
  **11ix**     0.09 ± 0.05                                 24.5 ± 2.1    2.66 ± 0.9    10.5 ± 2.3    1.5 ± 0.04    6.0 ± 1.5

All experiments were conducted in triplicate.

The treatment time was 24 hours for all experiments.

IC~50~ ± SD (half-maximal inhibitory concentration ± standard deviation) values for all compounds are expressed in micromolar units.

Electron paramagnetic resonance (EPR) analysis was further performed to characterize the radical species formed during the endoperoxide ring opening in the presence of Fe(II)SO~4~ as a catalyst (for the general procedure see [SI \#3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02600/suppl_file/ao9b02600_si_001.pdf)). [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} shows the EPR spectra of 2-methyl-nitrosopropane (MNP) adducts of artesunate derivatives **11iii, 11iv, 11ix**, and **11viii**, recorded as representative active samples (25 °C, *t* = 0), in comparison with the appropriate reference \[that is, the compound and MNP without the Fe(II) salt\].

![Room-temperature CW-EPR spectra of (a) **11iv**, (b) **11iii**, (c) **11ix**, and (d) blank, all recorded at *t* = 0 in the presence of the spin trap MNP. Experimental conditions: ν = 9.86GHz, 0.1 mT modulation amplitude, and 0.63 mW microwave power.](ao9b02600_0003){#fig2}

The EPR spectra of hybrid derivatives **11iv** and **11iii** ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}, lines a and b, respectively) show the same line shape with *g*~iso~ = 2.006 ± 0.0001, *A*~N~ = 1.49 ± 0.1mT, and *A*~H~ = 0.3±0.01mT. In accordance with the EPR results previously reported for artemisinin,^[@ref29]^ the magnetic parameters of artesunate derivatives **11iv** and **11iii** clearly identified the formation of a secondary C-centered radical.^[@ref30]^ The EPR signal decreased over time ([Figures S4 and S5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02600/suppl_file/ao9b02600_si_001.pdf), respectively). For hybrid derivative **11ix** (line c), the C-centered radical is present with a low intensity at *t* = 0, being stable during all recorded times (see [Figure S6](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02600/suppl_file/ao9b02600_si_001.pdf)). Unexpectedly, in the case of dimer derivative **11viii** ([Figure S8](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02600/suppl_file/ao9b02600_si_001.pdf)), no radical formation was detected (only at *t* = 90 min a very weak signal appeared, but it was no more present at *t* = 150 min). Note that artesunate alone showed a different behavior with respect to hybrids **11iv** and **11iii** ([Figure S7](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02600/suppl_file/ao9b02600_si_001.pdf)).

Even though a direct correlation between the in vitro EPR analysis of artemisinin derivatives and the in-cell anticancer activity cannot be made, in the case of compound **11iv**, the formation of a secondary C-centered radical was in accordance with the role suggested for this type of intermediate in the biological activity of artemisinin.^[@ref29]^ Moreover, the biological activity of **11iv** dropped after treatment with DFO, whereas that of compound **11viii**, deprived of an EPR signal, was unaffected by the DFO treatment.

Conclusions {#sec3}
===========

A library of novel derivatives with hybrid and dimer structures were synthesized by coupling between artesunate and dihydroartemisinin, with six phytochemicals, curcumin, eugenol, perillyl alcohol, tyrosol, and α- and δ-tocopherol. Among the novel derivatives, **11iii**--**iv**, **11viii**, and **11ix** showed a significant and selective anticancer activity. Moreover, the hybrid derivative, **11iv**, was characterized by a specific melanoma selectivity, being inactive against HeLa cells. This compound showed the formation of a secondary C-centered radical in the EPR analysis. DFO studies on the role of endoperoxide ring opening in the antimelanoma activity of **11iv** confirmed the relevant role of the formation of radical intermediates in the biological effect. Surprisingly, the anticancer activity of dimer **11viii** was not dependent on the formation of radical species, leaving open the possibility for other mechanisms to be operative. Further studies aimed at the determination of topoisomerase I as a possible target for the activity of these novel derivatives, as well as transcriptome comparison with other efficient antimelanoma drugs are still ongoing.

Experimental Section {#sec4}
====================

Chemistry: General Part {#sec4.1}
-----------------------

All reactions were performed in flame-dried glassware under a nitrogen atmosphere. Reagents were obtained from commercial suppliers (Sigma-Aldrich Srl, Milan, Italy) and used without further purification. TLC chromatography was performed on precoated aluminum silica gel SIL G/UV254 plates (Macherey-Nagel & Co.). The detection occurred via fluorescence quenching or development in a molybdato phosphate solution (10% in EtOH). Merck silica gel 60 was used for flash chromatography (23--400 mesh). All products were dried in high vacuum (10^-3^ mbar). ^1^H NMR and ^13^C NMR spectra were measured on a Bruker Avance DRX400 (400 MHz/100 MHz) and on a Bruker Avance DPX200 (200 MHz/50 MHz) spectrometers. Chemical shifts for protons are reported in parts per million (δ scale) and internally referenced to the CD~3~OD or CDCl~3~ signal at δ 3.33 and 7.28 ppm, respectively. Mass spectral (MS) data were obtained using an Agilent 1100 LC/MSD VL system (G1946C) with a 0.4 mL/min flow rate using a binary solvent system of 95:5 methyl alcohol/water. UV detection was monitored at 254 nm. Mass spectra were acquired in positive and negative mode scanning over the mass range. Elemental analyses (C, H, N) were performed in house. Artemisinin, dihydroartemisinin, and artesunate were obtained from Lachifarma s.r.l. (Zollino (LE), Italy).

### General Procedure for the Synthesis of Derivatives **11i**--**vii** {#sec4.1.1}

To a solution of artesunate (0.52 mmol, 1.0 equiv) in dry CH~2~Cl~2~ (3.0 mL), DCC (0.52 mmol, 1.0 equiv) and DMAP (0.16 mmol, 30 mol %) were added at room temperature. After the addition of the opportune phytochemical (0.52 mmol, 1.0 equiv), the reaction mixture was slowly stirred overnight (18 h) under a N~2~ atmosphere. The precipitated dicyclohexylurea was removed by filtration, and the solvent was removed under reduced pressure. The residue was purified by gradient column chromatography (hexane/EtOAc 1:1, 1:2).

#### Compound **11i** {#sec4.1.1.1}

Yield = 50%. *R*~*f*~ = 0.36 (hexane/EtOAc 1:2, molybdato phosphate). ^1^H NMR (CDCl~3~, 400 MHz): δ = 7.62 (d, 1H, *J* = 7.2 Hz), 7.58 (d, 1H, *J* = 7.2 Hz), 7.16--7.06 (m, 5H), 6.94 (d, 1H, *J* = 8.0 Hz), 6.57--6.46 (m, 2H), 5.85--5.81 (m, 2H), 5.46 (s, 1H), 3.95 (s, 3H), 3.88 (s, 3H), 2.98--2.92 (m, 2H), 2.88--2.84 (m, 2H), 2.62--2.57 (m, 1H), 2.43--2.34 (m, 1H), 2.04--1.47 (m, 6H), 1.45 (s, 3H), 1.41--1.30 (m, 2H), 1.08--1.00 (m, 1H), 0.98 (d, 3H, *J* = 5.7 Hz), 0.86 (d, 3H, *J* = 7.2 Hz) ppm. ^13^C NMR (CDCl~3~, 100 MHz): δ = 184.5, 183.3, 183.1, 181.9, 171.2, 170.9, 170.1, 151.4, 148.1, 147.9, 146.9, 141.1, 140.6, 134.1, 124.3, 123.0, 122.1, 114.9, 109.7, 104.5, 92.4, 92.3, 80.1, 60.4, 55.9, 51.6, 45.2, 37.3, 36.2, 34.1, 31.8, 29.1, 28.8, 25.9, 24.6, 22.1, 22.0, 21.0 20.2 12.0 ppm. MS (ESI): *m*/*z* for \[C~40~H~45~O~13~\]^−^: 733. Anal. calcd for C~40~H~46~O~13~: C, 65.38; H, 6.31; O, 28.31; found: C, 65.34; H, 6.30; O, 28.28.

#### Compound **11ii** {#sec4.1.1.2}

Yield = 49%. *R*~*f*~ = 0.70 (hexane/EtOAc 4:1, molybdato phosphate). ^1^H NMR (CDCl~3~, 200 MHz): δ = 6.95 (d, 1H, *J* = 8.0 Hz), 6.74--6.70 (m, 2H), 5.99--5.85 (m, 1H), 5.77 (d, 1H, *J* = 9.8 Hz), 5.42 (s, 1H), 5.08 (d, 1H, *J* = 6.8 Hz), 5.02 (s, 1H), 3.77 (s, 3H), 3.34 (d, 2H, *J* = 6.6 Hz), 2.96--2.76 (m, 4H), 2.60--2.41 (m, 1H), 2.04--1.47 (m, 6H), 1.41 (s, 3H), 1.30--1.05 (m, 4H), 0.93 (d, 3H, *J* = 5.2 Hz), 0.81 (d, 3H, *J* = 7.2 Hz) ppm. ^13^C NMR (CDCl~3~, 50 MHz): δ = 170.9, 170.4, 138.9, 137.9, 137.0, 122.5, 120.6, 116.1,112.7, 104.4, 92.2, 91.5, 80.1, 55.8, 51.6, 45.2, 40.0, 37.3, 36.2, 34.1, 31.8, 29.3, 28.7, 25.9, 24.6, 21.9, 20.2, 12.0 ppm. MS (ESI): *m*/*z* for \[C~29~H~39~O~9~\]^+^: 532. Anal. calcd for C~29~H~39~O~9~: C, 65.64; H, 7.22; O, 27.14; found: C, 65.67; H, 7.24; O, 27.16.

#### Compound **11iii** {#sec4.1.1.3}

Yield = 82%. *R*~*f*~ = 0.67 (hexane/EtOAc 4:1, molybdato phosphate). ^1^H NMR (CDCl~3~, 200 MHz): δ = 5.75 (d, 1H, *J* = 9.8 Hz), 5.72--5.71 (m, 1H), 5.39 (s, 1H), 4.68--4.66 (m, 2H), 4.43 (s, 2H), 2.71--2.61 (m, 4H), 2.60--2.41 (m, 1H), 2.39--2.25 (m, 1H), 2.12--1.76 (m, 10H), 1.69 (s, 3H), 1.63--1.41 (m, 3H), 1.38 (s, 3H), 1.35--1.17 (m, 3H), 1.16--0.94 (m, 1H), 0.92 (d, 3H, *J* = 5.6 Hz), 0.81 (d, 3H, *J* = 7.2 Hz) ppm. ^13^C NMR (CDCl~3~, 50 MHz): δ = 171.9, 171.0, 149.5, 132.4, 125.9, 108.7, 104.4, 92.1, 91.5, 80.0, 68.7, 51.5, 45.2, 40.7, 37.2, 34.1, 31.8, 30.4, 29.2, 28.9, 27.2, 26.3, 26.1, 25.8, 24.5, 21.9, 20.7, 20.2, 12.0 ppm. MS (ESI): *m*/*z* for \[C~29~H~43~O~8~\]^+^: 519. Anal. calcd for C~29~H~42~O~8~: C, 67.16; H, 8.16; O, 24.68; found: C, 67.17; H, 8.14; O, 24.66.

#### Compound **11iv** {#sec4.1.1.4}

Yield = 53%. *R*~*f*~ = 0.50 (hexane/EtOAc 4:1, molybdato phosphate). ^1^H NMR (CDCl~3~, 200 MHz): δ = 7.17 (d, 2H, *J* = 8.6 Hz), 6.98 (d, 1H, *J* = 8.6 Hz), 5.78 (d, 1H, *J* = 10.0 Hz), 5.40 (s, 1H), 3.76 (t, 2H, *J* = 6.6 Hz), 2.85--2.75 (m, 6H), 2.55--2.51 (m, 1H), 2.34--2.25 (m, 1H), 2.02--1.41 (m, 6H), 1.41 (s, 3H), 1.35--0.99 (m, 4H), 0.91 (d, 3H, *J* = 5.4 Hz), 0.80 (d, 3H, *J* = 7.2 Hz) ppm. ^13^C NMR (CDCl~3~, 50 MHz): δ = 170.9, 170.8, 149.1, 136.3, 129.9, 121.5, 104.5, 92.3, 91.5, 80.1, 63.5, 51.5, 45.2, 38.5, 37.2, 36.2, 34.1, 31.8, 29.2, 29.0, 25.8, 24.6, 21.9, 20.2, 14.2, 12.0 ppm. MS (ESI): *m*/*z* for \[C~27~H~36~O~9~Na\]^+^: 528. Anal. calcd for C~27~H~36~O~9~: C, 64.27; H, 7.19; O, 28.54; found: C, 64.28; H, 7.20; O, 28.55.

#### Compound **11v** {#sec4.1.1.5}

Yield = 72%. *R*~*f*~ = 0.19 (hexane/EtOAc 9:1, molybdato phosphate). ^1^H NMR (CDCl~3~, 200 MHz): δ = 6.65--6.58 (m, 2H), 5.80 (d, 1H, *J* = 9.8 Hz), 5.42 (s, 1H), 2.91--2.60 (m, 8H), 2.58--2.45 (m, 1H), 2.36--2.21 (m, 1H), 2.04 (s, 3H), 2.02--1.05 (m, 25H), 1.41 (s, 3H), 1.23 (s, 3H), 0.94 (d, 3H, *J* = 5.8 Hz), 0.89--0.80 (m, 18H) ppm. ^13^C NMR (CDCl~3~, 50 MHz): δ = 171.3, 170.9, 149.7, 142.3, 127.2, 121.0, 120.8, 118.9, 104.4, 92.2, 91.5, 80.0, 51.5, 45.2, 40.1, 39.3, 37.4, 37.2, 34.1, 32.7, 32.6, 31.7, 29.2, 28.9, 25.9, 24.6, 24.4, 24.2, 22.7, 22.6, 22.4, 22.0, 21.0, 20.2, 19.7, 19.6, 16.0, 12.4 ppm. MS (ESI): *m*/*z* for \[C~46~H~73~O~9~\]^+^: 769. Anal. calcd for C~46~H~72~O~9~: C, 71.84; H, 9.44; O, 18.72; found: C, 71.87; H, 9.43; O, 18.75.

#### Compound **11vi** {#sec4.1.1.6}

Yield = 60%. *R*~*f*~ = 0.27 (hexane/EtOAc 9:1, molybdato phosphate). ^1^H NMR (CDCl~3~, 200 MHz): δ = 5.80 (d, 1H, *J* = 9.8 Hz), 5.42 (s, 1H), 2.96--2.70 (m, 4H), 2.56--2.49 (m, 3H), 2.45--2.21 (m, 1H), 2.36--2.21 (m, 1H), 2.02 (s, 3H), 1.99 (s, 3H), 1.95 (s, 3H), 1.87--1.01 (m, 8H), 0.95--0.81 (m, 18H) ppm. ^13^C NMR (CDCl~3~, 50 MHz): δ = 170.9, 170.7, 149.4, 140.5, 126.7, 124.9, 122.9, 117.3, 104.4, 92.3, 91.5, 80.0, 75.0, 51.6, 45.2, 39.4, 37.4, 37.3, 37.2, 36.2, 34.1, 32.8, 32.7, 31.8, 29.2, 27.9, 25.9, 24.8, 24.4, 22.7, 22.6, 22.0, 21.0, 20.2, 19.8, 19.7, 12.9, 12.1, 11.8 ppm. MS (ESI): *m*/*z* for \[C~48~H~76~O~9~\]^+^: 784. Anal. calcd for C~46~H~72~O~9~: C, 72.33; H, 9.61; O, 18.06; found: C, 72.31; H, 9.62; O, 18.05.

### General Procedure for the Synthesis of Derivatives **11vii** and **11viii**: {#sec4.1.2}

To a solution of artesunate (0.52 mmol, 1.0 equiv) in dry CH~2~Cl~2~ (3.0 mL), DCC (1.04 mmol, 2.0 equiv) and DMAP (0.32 mmol, 60 mol %) were added at room temperature. After the addition of the opportune phytochemical (1.04 mmol, 2.0 equiv), the reaction mixture was slowly stirred overnight (18 h) under a N~2~ atmosphere. The precipitated dicyclohexylurea was removed by filtration, and the solvent was removed under reduced pressure. The residue was purified by gradient column chromatography (hexane/EtOAc 1:1, 1:2).

#### Compound **11vii** {#sec4.1.2.1}

Yield = 47%. *R*~*f*~ = 0.50 (hexane/EtOAc 9:1, molybdato phosphate). ^1^H NMR (CDCl~3~, 200 MHz): δ = 7.00 (d, 2H, *J* = 8.6 Hz), 6.81 (d, 2H, *J* = 8.6 Hz), 5.59 (d, 1H, *J* = 6.4 Hz), 5.54 (d, 1H, *J* = 6.4 Hz), 5.24 (s, 1H), 5.22 (s, 1H), 4.05 (t, 2H, *J* = 7.0 Hz), 2.74--2.57 (m, 6H), 2.50--2.25 (m, 6H), 2.20--2.06 (m, 2H), 1.84--1.19 (m, 12H), 1.18 (s, 3H), 1.17 (s, 3H), 1.11--0.82 (m, 8H), 0.74 (d, 6H, *J* = 5.8 Hz), 0.64--0.60 (m, 6H) ppm. ^13^C NMR (CDCl~3~, 50 MHz): δ = 171.7, 170.8, 170.7, 170.5, 149.16, 135.2, 129.7, 129.6, 121.4, 104.1, 92.1, 92.0, 91.3, 79.9, 64.8, 51.4, 48.4, 45.0, 37.0, 36.0, 34.2, 33.9, 33.7, 31.6, 30.6, 30.3, 29.8, 29.4, 29.0, 28.9, 28.8, 28.6, 25.6, 24.8, 24.4, 21.7, 20.0, 11.8, 11.7 ppm. MS (ESI): *m*/*z* calcd for \[C~45~H~61~O~16~\]^+^: 856. Anal. calcd for C~45~H~60~O~16~: C, 63.07; H, 7.06; O, 29.87; found: C, 63.08; H, 7.05; O, 29.85.

#### Compound **11viii** {#sec4.1.2.2}

Yield = 59%. *R*~*f*~ = 0.39 (hexane/EtOAc 9:1, molybdato phosphate). ^1^H NMR (CDCl~3~, 200 MHz): δ = 7.57 (d, 2H, *J* = 15.8 Hz), 7.13--7.02 (m, 6H), 6.52 (d, 2H, *J* = 15.8 Hz), 5.83--5.76 (m, 2H), 5.40 (s, 2H), 3.82 (s, 6H), 2.97--2.76 (m, 8H), 2.59--2.48 (m, 2H), 2.42--2.26 (m, 2H), 2.12--1.50 (m, 12H), 1.46 (s, 6H), 1.39--0.99 (m, 8H), 0.91 (d, 6H, *J* = 5.4 Hz), 0.74 (d, 6H, *J* = 18.2 Hz) ppm. ^13^C NMR (CDCl~3~, 50 MHz): δ = 183.1, 170.8, 170.1, 151.3, 141.2, 139.9, 134.0, 124.3, 123.3, 121.1, 111.4, 104.4, 101.8, 92.3, 91.5, 80.1 60.3, 55.9, 51.5, 45.2, 37.2, 36.2, 34.1, 31.8, 29.2, 28.7, 25.9, 25.0, 24.6, 22.0, 20.2, 14.2, 12.0 ppm.MS (ESI): *m*/*z* for \[C~59~H~73~O~20~\]^+^: 1101. Anal. calcd for C~59~H~72~O~20~: C, 64.35; H, 6.59; O, 29.06; found: C, 64.31; H, 6.62; O, 29.05.

### Procedure for the Synthesis of Derivative **11ix** {#sec4.1.3}

To a solution of artesunic acid (0.52 mmol, 1.0 equiv) in dry DMF (3.0 mL), K~2~CO~3~ (1.04 mmol, 2.0 equiv) and 4-hydroxyphenethyl bromide (0.52 mmol, 1.0 equiv) were added at room temperature. The reaction mixture was warmed at 90 °C and stirred overnight (18 h) under a N~2~ atmosphere. After this time, the precipitate was removed by filtration, and the solution was diluted with H~2~O (20 mL) and extracted with EtOAc (3 × 25 mL). The organic phase was washed with brine dried over Na~2~SO~4~, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (hexane/EtOAc 1:1).

Yield = 46%. *R*~*f*~ = 0.33 (hexane/EtOAc 4:1, molybdato phosphate). ^1^H NMR (CDCl~3~, 200 MHz): δ = 7.04 (d, 2H, *J* = 8.4 Hz), 6.76 (d, 2H, *J* = 8.4 Hz), 5.75 (d, 2H, *J* = 9.8 Hz), 5.42 (s, 2H), 4.22 (t, 2H, *J* = 7.0 Hz), 2.83 (d, 2H, *J* = 7.0 Hz), 2.63--2.48 (m, 4H), 2.35--2.28 (m, 2H), 1.97--1.42 (m, 6H), 1.41 (s, 3H), 1.27--0.99 (m, 4H), 0.91 (d, 3H, *J* = 3.8 Hz), 0.80 (d, 3H, *J* = 7.0 Hz) ppm. ^13^C NMR (CDCl~3~, 50 MHz): δ = 172.0, 171.1, 151.2, 130.0, 129.6, 115.5, 104. 6, 92.2, 91.5, 80.2, 65.4, 51.5, 45.2, 37.3, 36.2, 34.1, 34.0, 33.2, 31.8, 29.7, 29.1, 28.9, 28.0, 25.9, 24.6, 22.7, 22.0, 21.0, 20.2, 14.2, 13.2, 12.0 ppm. MS (ESI): *m*/*z* for \[C~27~H~35~O~9~\]^−^: 503. Anal. calcd for C~27~H~36~O~9~: C, 64.27; H, 7.19; O, 28.54; found: C, 64.29; H, 7.18; O, 28.53.

### Procedure for the Synthesis of Derivative **11x** {#sec4.1.4}

To a solution of dihydroartemisinin (0.52 mmol, 1.0 equiv) in dry DMF (3.0 mL), K~2~CO~3~ (1.04 mmol, 2.0 equiv) and 4-hydroxyphenethyl bromide (0.52 mmol, 1.0 equiv) were added at room temperature. The reaction mixture was warmed at 90 °C and stirred overnight (18 h) under a N~2~ atmosphere. After this time, the precipitate was removed by filtration, and the solution was diluted with H~2~O (20 mL) and extracted with EtOAc (3 × 25 mL). The organic phase was washed with brine dried over Na~2~SO~4~, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography (hexane/EtOAc 1:1).

Yield = 53% (a mixture of α and β isomers). *R*~*f*~ = 0.27 (hexane/EtOAc 9:1, molybdato phosphate). ^1^H NMR (CDCl~3~, 200 MHz): δ = 7.06--7.00 (m, 2H), 6.76--6.69 (m, 2H), 5.11 (s, 1H), 4.74 (d, *J* = 3.4 Hz), 4.04--3.92 (m, 1H), 3.57--3.46 (m, 1H), 2.80--2.72 (m, 2H), 2.56--2.51 (m, 1H), 2.37--2.30 (m, 1H), 2.29--1.41 (m, 6H), 1.39 (s, 3H), 1.37--0.91 (m, 4H), 0.90--0.85 (m, 3H), 0.82 (d, 3H, *J* = 7.4 Hz) ppm. ^13^C NMR (CDCl~3~, 50 MHz): δ = 154.2, 131.2, 130.9, 130.0, 115.1, 115.0, 104.1, 103.2, 102.8, 101.7, 88.8, 87.9, 81.1, 69.5, 69.1, 52.4, 51.9, 46.2, 44.2, 39.4, 37.2, 37.1, 36.5, 36.4, 35.4, 34.6, 34.4, 31.4, 30.9, 26.1, 25.9, 24.6, 24.2, 20.3, 20.0, 19.5, 12.9 ppm. MS (ESI): *m*/*z* for \[C~23~H~31~O~6~\]^−^: 403. Anal. calcd for C~23~H~32~O~6~: C, 68.29; H, 7.97; O, 23.73; found: C, 68.230; H, 7.99; O, 23.74.

Biological Part {#sec4.2}
---------------

### Cell Culture Condition {#sec4.2.1}

The C3PV cell line is a primary human fibroblast grown according to Botta et al.^[@ref31]^ SK-MEL3, SK-MEL24 and RPMI-7951 are three different metastatic melanoma cancer cell lines. SK-MEL3 was grown in McCoy's medium supplemented with 15% fetal bovine serum (FBS), penicillin (100 U/mL), and streptomycin (1 mg/mL). SK-MEL24 and RPMI-7951 were grown in Eagle's minimum essential medium containing 15 and 10% FBS, respectively, penicillin (100 U/mL), and streptomycin (1 mg/mL). All cell lines were maintained at 37 °C in a humidified atmosphere (95%) and 5% CO~2~.

### Treatment Protocol: General Procedure {#sec4.2.2}

To study the effect of artemisinin and its derivatives on cell viability, the C3PV, SK-MEL3, SK-MEL24, and RPMI-7951 cell lines were seeded in 96-well plates (6000 cells/well in 100 μL of medium) and incubated overnight to allow cell adherence. Afterward, the medium was replaced with fresh medium containing the appropriate dose of compounds. Artemisinin and its derivatives were used in a range of 0.01 to 1 μM for 24 h. The analyses of cell viability were done at the end of treatment. The assays were performed in quadruplicate for both treatments.

### Treatment Protocol for DFO Assay {#sec4.2.3}

To study the mechanism of action of artemisinin and compounds **11iii**, **11iv**, **11viii**, and **11ix**, the SK-MEL3, SK-MEL24 and RPMI-7951 cell lines were seeded in 96-well plates (6000 cells/well in 100 μL of medium) and incubated overnight to allow cell adherence. Afterward, the medium was replaced with fresh medium containing DFO (20 μM) for 1 h. Then the appropriate dose of artemisinin and its compounds **11iii**, **11iv**, and **11viii** were added for 24 h. The analyses of cell viability were done at the end of treatment. The assays were performed in quadruplicate for both treatments.

### Cell Viability Assay {#sec4.2.4}

Cell viability was evaluated using MTT \[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide\] cell proliferation assay. Briefly, after incubation for 3 h at 37 °C with MTT (0.5 mg/mL), the supernatant was replaced with 100 μL of analysis solution containing 10% sodium dodecyl sulfate and 0.6% acetic acid in dimethyl sulfoxide to dissolve the formazan crystals. Optical density measurements were performed with a scanning spectrophotometer DTX880 Multimode Detector (Beckman Coulter) using a 630 nm (background) and a 570 nm filter.

### Statistical Analysis {#sec4.2.5}

The IC~50~ values were determined by nonlinear regression using the program, graphpad prism 6. The SI values were calculated using the formula
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